Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity to block complement activation. Ravulizumab can be used for the prevention and treatment of paroxysmal sleep hemoglobinuria, atypical hemolytic uremic syndrome and myasthenia gravis.